{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/eczema-atopic/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"d176eafc-9dcd-5f10-84a7-1d302a858223","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field f987ecd3-3fc4-4224-bd78-10d87cc42342 --><h2>Changes</h2><!-- end field f987ecd3-3fc4-4224-bd78-10d87cc42342 -->","summary":null,"htmlStringContent":"<!-- begin item 8fbea728-173b-4133-880d-d04f0e2f451c --><!-- begin field d8432558-e6ed-4377-b5f4-e50d41c06da4 --><p><strong>January 2021 </strong>— minor update. Contraindications and drug interactions for erythromycin have been updated in line with an MHRA drug safety update. </p><!-- end field d8432558-e6ed-4377-b5f4-e50d41c06da4 --><!-- end item 8fbea728-173b-4133-880d-d04f0e2f451c -->","topic":{"id":"63a4e43b-49fe-563e-ac98-e9b0859c592c","topicId":"68307f26-e94a-48b4-9595-fadcb2fdee8a","topicName":"Eczema - atopic","slug":"eczema-atopic","lastRevised":"Last revised in January 2021","chapters":[{"id":"168b58b7-fdd4-50a2-b9ec-27d907398222","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"8bb5c02b-0104-5f27-98ba-1b53ded774ba","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"98e1b8e0-503c-57ac-9ef2-caacc212e152","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d176eafc-9dcd-5f10-84a7-1d302a858223","slug":"changes","fullItemName":"Changes"},{"id":"6d4019a1-b2bb-54e9-895a-a2edc7b87429","slug":"update","fullItemName":"Update"}]},{"id":"9c4faee5-cf0b-515b-bc4a-a31602a94782","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"538ef47b-cfe7-5fca-beb8-19aa8e5bf9c1","slug":"goals","fullItemName":"Goals"},{"id":"a0383042-27f4-54a3-a484-e3a5a53f6625","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"2c77a3c3-9932-5d7d-91b5-418e832f5312","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"8baad0b5-8401-5866-829c-d480e381e783","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a521d8b1-827a-5781-ad45-f3791b4e1bd1","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8cf8749d-acfe-5549-ab78-d5cf32ea5fbf","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"a7eb5aa7-360a-51dc-8e4c-daad28913df0","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"5a643f13-59c4-52ad-b851-dc4e8a73f354","slug":"definition","fullItemName":"Definition"},{"id":"ebbfabd2-e0e3-5987-aa33-c3fa2ba187da","slug":"causes","fullItemName":"Causes"},{"id":"e7a40326-66ce-59e3-bdcb-86b1b0b611ea","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9944d177-a960-52fd-8b8c-6d34afadddcb","slug":"complications","fullItemName":"Complications"},{"id":"01750b87-b8f0-5ec7-bda0-23ae3f563218","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"9692db09-38c6-5f1b-bc48-0e6606729c0c","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"4ff05ba7-7a47-5830-a6d0-a3c723344964","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"b23630ce-69bb-56e8-9fae-e120331f815f","slug":"identifying-trigger-factors","fullItemName":"Identifying trigger factors"},{"id":"9cf9065e-b2c1-545d-a347-325c756ba267","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"084c2672-a546-5c1a-925f-c2b2579ea662","fullItemName":"Management","slug":"management","subChapters":[{"id":"d5478272-79bf-561d-86b2-264a10149cc9","slug":"assessment","fullItemName":"Scenario: Assessment"},{"id":"0cccd619-b2de-56ab-aa4b-8335f760ada1","slug":"mild-eczema","fullItemName":"Scenario: Mild eczema"},{"id":"fd373e1c-c93c-5467-8984-3ffb57f4db96","slug":"moderate-eczema","fullItemName":"Scenario: Moderate eczema"},{"id":"60c5ed4a-3cf7-5f16-a959-9ebb082384a8","slug":"severe-eczema","fullItemName":"Scenario: Severe eczema"},{"id":"b127c625-6749-5a79-839f-88edee29b634","slug":"infected-eczema","fullItemName":"Scenario: Infected eczema"},{"id":"be3c1aab-3810-578d-a12d-7fa8a3bda3af","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"7a62824e-ab17-5ec8-b4eb-832ae0ea1ed2","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a6a60e24-add6-5b81-96c6-7556a07ce5ef","slug":"stepped-approach-to-treatment","fullItemName":"Stepped approach to treatment"},{"id":"32834cc1-317c-5325-a3c6-54b2bfa53088","slug":"emollients","fullItemName":"Emollients"},{"id":"93edf0ec-6483-5c88-a432-bb01d2b3b606","slug":"topical-corticosteroids","fullItemName":"Topical corticosteroids"},{"id":"33241bf6-534a-5809-8c00-641507b16a6b","slug":"oral-antihistamines","fullItemName":"Oral antihistamines"},{"id":"f30bf02b-a3bb-581a-bc1f-853575c7f434","slug":"oral-corticosteroids","fullItemName":"Oral corticosteroids"},{"id":"6432a48a-76f3-534e-a4c1-8ec000fe6d58","slug":"oral-antibiotics","fullItemName":"Oral antibiotics"},{"id":"24b6d226-2567-5496-8557-dbfabde4e855","slug":"topical-antibiotics-antiseptics","fullItemName":"Topical antibiotics and antiseptics"}]},{"id":"a24fe8c8-994b-5b5d-a725-12ab08a2b0e6","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"aaad8885-ddf1-52ea-9dbb-520435cbe52b","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"2a17d479-605d-53c6-aac4-d2dee258e56e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"134abf73-7ae8-51e1-9f52-342c5379bcb0","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"5fa037f5-1815-5c07-ad67-d491a2c34652","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"4a76468f-46d6-51a1-9527-915b5596d2ad","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"15077c82-8b21-52ca-88cb-b5b956cd2ae6","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"cc9ef2ce-7217-5486-b5fe-23241bc45da4","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"98e1b8e0-503c-57ac-9ef2-caacc212e152","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"435b038d-4b0f-5d76-9890-ceac12d8ee91","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field ced27ec7-70f1-4590-8566-0089596445c8 --><h3>Previous changes</h3><!-- end field ced27ec7-70f1-4590-8566-0089596445c8 -->","summary":null,"htmlStringContent":"<!-- begin item ec27105a-b45c-4c81-9980-45707cd52fa0 --><!-- begin field 3a5ec3fd-62bd-454a-a980-e458aa6f39c9 --><p><strong>April 2020</strong> — minor update. New management scenario created to provide information regarding COVID-19. </p><p><strong>January 2018</strong> — minor update. Adverse effect section of non-sedating antihistamines updated to reflect changes to SPC.</p><p><strong>March 2017 </strong>— reviewed. A literature search was conducted in February 2017 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials (RCTs) published since the last revision of the topic. No major changes to clinical recommendations have been made, but the topic has been restructured.</p><p><strong>October 2016</strong> — minor update. Information on the risk of fire from using large amounts of paraffin-based emollients has been added, based on information in the Summary of Product Characteristics (SPC) for E45<sup>®</sup> Cream (ABPI, 2016). </p><p><strong>July 2015 </strong>—<strong> </strong>minor update. The prescribing information sections on erythromycin and clarithromycin have been clarified.</p><p><strong>March 2013 </strong>— reviewed. A literature search was conducted in January 2013 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials (RCTs) published since the last revision of the topic. No major changes to clinical recommendations have been made; however, a link to the National Institute for Health and Care Excellence (NICE) guideline <a href=\"http://www.nice.org.uk/nicemedia/live/13348/57929/57929.pdf\" data-hyperlink-id=\"59ddc247-2e84-43ca-8940-a8f7015a949e\">Food allergy in children and young people. Diagnosis and assessment of food allergy in children and young people in primary care and community settings (pdf)</a> (NICE, 2011) has been provided for information on how to diagnose and manage a suspected food allergy in primary care.</p><p><strong>June 2012 </strong>— minor update. Minor typographical error corrected.</p><p><strong>January 2012 </strong>— minor update. Strength and generic name of Dermovate<sup>® </sup>corrected in prescribing information. Issued in February 2012.</p><p><strong>August 2011 </strong>— minor update. The recommendation on when to swab people with eczema has been clarified. Issued in September 2011.</p><p><strong>July 2011 </strong>— minor update. Typographical errors corrected in the sections on treatment of moderate flares of eczema and advice for people using emollients and topical corticosteroids. Issued in July 2011.</p><p><strong>April 2011 </strong>— minor update. Additional recommendations from the Scottish Intercollegiate Guidelines Network (SIGN) guideline <em>Management of atopic eczema in primary care </em>(SIGN, 2011) have been incorporated into this topic. Issued in June 2011.</p><p><strong>October 2010 </strong>— technical update. The management section of this topic has been simplified to improve clarity and navigation. There have been no changes to the clinical content or meaning of the recommendations.</p><p><strong>October 2010 </strong>— minor update. Chlorphenamine is no longer licensed for the treatment of pruritus. Text and prescriptions amended to reflect this. Issued in October 2010.</p><p><strong>October 2008 </strong>— minor update to usage instructions for diprobase cream. Issued in November 2008.</p><p><strong>March to July 2008 </strong>— converted from CKS guidance to CKS topic structure. The evidence base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. Prescriptions for emollients and topical corticosteroids have been reduced in scope to only include the most commonly prescribed products, as it is not feasible (or helpful to prescribers) to include all available products. Prescriptions for sedating antihistamines, non-sedating antihistamines, and topical antibiotics have been added in accordance with NICE recommendations.</p><p><strong>September 2008 </strong>— minor update to text. Issued in September 2008.</p><p><strong>January 2006 </strong>— minor update to include prescriptions for Hydromol<sup>® </sup>emollient products. Issued in February 2006.</p><p><strong>October 2005 </strong>— minor technical update. Issued in November 2005.</p><p><strong>February 2005 </strong>— minor formatting update. Desoximetasone 0.05% oily cream discontinued and prescriptions removed.</p><p><strong>July 2004 </strong>— written. Validated in September 2004 and issued in November 2004.</p><!-- end field 3a5ec3fd-62bd-454a-a980-e458aa6f39c9 --><!-- end item ec27105a-b45c-4c81-9980-45707cd52fa0 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}